Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra) in Subjects With Primary Immunodeficiency

Trial Profile

An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra) in Subjects With Primary Immunodeficiency

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Therapeutic Use
  • Acronyms HiLo
  • Sponsors CSL Behring
  • Most Recent Events

    • 21 Apr 2020 According to a CSL Behring media release, results from this trial were published in an online supplement to The Journal of Allergy and Clinical Immunology.
    • 21 Apr 2020 Results presented in the CSL Behring media release.
    • 16 Mar 2020 Results (N=16), of manual push flow rate cohort assessing safety of subcutaneous IgPro20 administration via manual push at high flow rates, published on 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top